Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
54 results about "Stearoyl-CoA Desaturase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An enzyme that catalyzes the formation of oleoyl-CoA, A, and water from stearoyl-CoA, AH2, and oxygen where AH2 is an unspecified hydrogen donor.
Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
InactiveUS20080167321A1Lower blood lipid levelsEffective to modulate triglyceride levelOrganic active ingredientsOrganic chemistryDiseasePyridine
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, W, V, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-Desaturase
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, Q, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a arc defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I):where x, y, G, J, K, L, M, V R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase
InactiveUS20070299081A1Lower blood lipid levelsEffective to modulate triglyceride levelBiocideOrganic chemistryDiseaseStearoyl-CoA Desaturase
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8, and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors
InactiveUS20080188488A1Lower blood lipid levelsEffective to modulate triglyceride levelOrganic active ingredientsOrganic chemistryDiseaseStearoyl-CoA Desaturase
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
Owner:XENON PHARMACEUTICALS INC
Acetylene derivatives as stearoyl coa desaturase inhibitors
The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and / or disorders modulated by Stearoyl CoA Desaturase 1 (SCD1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and / or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.
Owner:GLENMARK PHARMA SA
Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
The present invention relates to substituted thiadiazole compounds of the formula (I):and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.
Owner:BOUILLOT ANNE MARIE JEANNE +5
New compounds
InactiveUS20080255153A1Regulate compositionRegulate lipid levelOrganic active ingredientsBiocideNervous systemNeonatal diabetes
The present invention relates to compounds of formula (I):and pharmaceutically acceptable salts thereof, which are useful as inhibitors of human stearoyl-CoA desaturase (SCD). The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, metabolic syndrome, neurological diseases, immune disorders, cancer and various skin diseases.
Owner:INOVACIA
Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
InactiveUS20060154252A1Reduce accumulationReducing and monitoring growthMicrobiological testing/measurementPharmaceutical active ingredientsPhospholipasePhosphate
The present invention relates to a method for identifying therapeutic agents for reducing and monitoring the growth, erosion, rupture or stability of an atherosclerotic plaque comprising the analysis of the differential expression of at least two genes coding proteins chosen among among Stearoyl CoA desaturase, Phosphatidic acid phosphate, and Phosphoinositide-specific-phospholipase-B1, eventually in association with the analysis of the differential expression of at least one gene coding a protein choosen in the group comprising Aldose reductase and aldehyde reductase, Sphingomyelinase, Acid ceramidase, Ceramide glucosyl transferase, Sphingosin phosphate liase, Thymosine beta 4, Aldehyde dehydogenase, ATPase Ca++ binding protein and CD163.
Owner:MARGUERIE GERARD +1
Antisense modulation of stearoyl-CoA desaturase expression
Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.
Owner:IONIS PHARMA INC
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Owner:FOREST LAB HLDG LTD
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Owner:FOREST LAB HLDG LTD
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
InactiveUS8071603B2Organic active ingredientsOrganic chemistryStearoyl-CoA DesaturaseHeterocyclic derivatives
Owner:XENON PHARMACEUTICALS INC
Inhibitors of stearoyl-coa desaturase
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
Owner:F HOFFMANN LA ROCHE INC
Piperidine derivatives as inhibitors of stearoyl-CoA desaturase
The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Owner:FOREST LAB HLDG LTD
Composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity
InactiveUS20070110833A1Potent luciferase activityAdjust lipid metabolismBiocideMetabolism disorderDiseaseAdipogenesis
The present invention is related to an extract of Cucurbitaceae family plant or the purified extract isolated therefrom having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The extract of Cucurbitaceae family plant of the present invention showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR α and δ, reducing activity of the gene expression of stearoyl-CoA desaturase, and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food.
Owner:HELIXIR
Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
InactiveUS20050256033A1Lower levelImportant cardioprotective benefitBiocideFungiDisease causeStearoyl-CoA Desaturase
The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and / or treatment of such diseases.
Owner:XENON PHARMACEUTICALS INC +1
Oleaginous microalgae having an LPAAT ablation
Recombinant DNA techniques are used to produce oleaginous recombinant cells that produce triglyceride oils having desired fatty acid profiles and regiospecific or stereospecific profiles. Genes manipulated include those encoding stearoyl-ACP desaturase, delta 12 fatty acid desaturase, acyl-ACP thioesterase, ketoacyl-ACP synthase, lysophosphatidic acid acyltransferase, ketoacyl-CoA reductase, hydroxyacyl-CoA dehydratase, and / or enoyl-CoA reductase. The oil produced can have enhanced oxidative or thermal stability, or can be useful as a frying oil, shortening, roll-in shortening, tempering fat,cocoa butter replacement, as a lubricant, or as a feedstock for various chemical processes. The fatty acid profile can be enriched in midchain profiles or the oil can be enriched in triglycerides of the saturated-unsaturated-saturated type.
Owner:CORBION BIOTECH INC
Inhibitors of stearoyl-CoA desaturase
Owner:F HOFFMANN LA ROCHE INC
Method for evaluating quality of beef such as taste and texture on the basis of genotype of stearoyl-coa desaturase
ActiveUS20070077558A1Simply and efficiently evaluatingBioreactor/fermenter combinationsBiological substance pretreatmentsAnimal scienceStearyl-CoA
We paid attention to stearoyl-CoA desaturase gene, and investigated the relation between this gene and the unsaturated fatty acid content in beef fat. As a result, we found that the unsaturated fatty acid content was associated with the genotype of this gene, classified according to several single nucleotide polymorphisms (SNPs) on this gene. The present invention is a method to predict the unsaturated fatty acid content in beef (or milk) fat, on the basis of the genotype of bovine stearoyl-CoA desaturase, and useful prediction method for beef quality such as taste and texture.
Owner:THE NEW IND RES ORG
Expression systems for mammalian and mycobacterial desaturases
Expression system for components of a desaturase complex is provided. The system includes expression of a desaturase and an oxidoreductase. The system may be used for expression of mycobacterial desaturases or for expression of mammalian desaturases. The system may further include cell-free expression of other components of the desaturase complex. The expression system may include expression of stearoyl-CoA. The expression system may further include expression of cytochrome b5. The expression system may also include expression of cytochrome b5 reductase. The expression system may also include expression of Rv3230c. In addition, methods for assaying the activity of a stearoyl-CoA desaturase in vitro are provided.
Owner:WISCONSIN ALUMNI RES FOUND
Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Owner:FOREST LAB HLDG LTD
RNA INTERFERENCE MEDIATED INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
InactiveUS20090099118A1Improves various propertyImprove the immunityCompounds screening/testingOrganic active ingredientsDouble stranded rnaGene expression
Owner:MERCK SHARP & DOHME CORP
Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
Owner:FOREST LAB HLDG LTD
Stearoyl CoA desaturase transgenic non-human animals
The present invention provides transgenic, non-human animals that include a transgene that encodes a fatty acid desaturase, e.g., stearoyl-CoA desaturase, and methods for producing such animals. The invention further provides an expression cassette that includes a coding region for a desaturase such as stearoyl-CoA desaturase, operably linked to a heterologous, tissue-specific animal cell promoter. The invention further provides methods of producing a food product, such as milk, meat, or eggs, using a subject transgenic non-human animal, as well as food products harvested from a subject transgenic non-human animal.
Owner:RGT UNIV OF CALIFORNIA
New compounds
InactiveUS20080221129A1Regulate compositionRegulate lipid levelBiocideOrganic active ingredientsDisease causeStearoyl-CoA Desaturase
The present invention relates to compounds of the formula (I):including pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, and N-oxides thereof, said compounds being useful as inhibitors of stearoyl-CoA desaturase (SCD). The invention further relates to the use of compounds of the formula (I) for treatment of medical conditions in which the modulation of SCD activity is beneficial, such as cardiovascular diseases, obesity, non-insulin-dependent diabetes mellitus, hypertension, neurological diseases, immune disorders, cancer, essential fatty acid deficiency, acne, psoriasis, rosacea or other skin conditions.
Owner:BIOVITRUM AB (PUBL)
Acetylene derivatives as stearoyl coa desaturase inhibitors
The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors, hi particular, compounds described herein are useful for treating or preventing diseases, conditions and / or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and / or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.
Owner:GLENMARK PHARMACEUTICALS LIMITED
Antisense modulation of stearoyl-CoA desaturase expression
InactiveUS20050043256A1Modulate expressionSugar derivativesPeptide/protein ingredientsDiseaseStearyl-CoA
Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.
Owner:IONIS PHARMA INC
Heterocyclic organic compounds
Owner:NOVARTIS AG +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com